No Data
Shendu Company yifeng pharmacy chain (603939): Performance steadily growing, continuous expansion of stores in each region.
The company released the third quarter report for 2024, achieving revenue of 17.219 billion yuan in Q1-Q3 of 2024, an 8.38% year-on-year increase, and achieving a net income attributable to the parent company of 1.111 billion yuan, an 11.14% year-on-year increase.
AVIC Securities: Pharmaceutical industry performance under pressure in the third quarter, total market value of heavyweight in fund holdings increased.
The demand for blood sector in biological products remains high, with vaccines facing sales pressure due to factors such as previous market consumption; active pharmaceutical ingredients are entering the tail end of downstream inventory, showing an improvement in demand, and future performance is expected to gradually improve.
Donghai Securities: The chain pharmacy industry is accelerating consolidation, and the concentration continues to increase.
In 2023, the total market size of pharmaceutical stores is about 650 billion yuan, with a CAGR of 9.07% from 2015 to 2023. The retail pharmacy terminal sales scale accounts for 29.3% of the national pharmaceutical sales terminal.
Sinolink Securities: Medical industry sentiment in the third quarter hovers at the bottom, focusing on the improvement prospects for the next 25 years.
In the third quarter, due to internal adjustments in the medical sector, changes in the overall consumer environment, and some medical insurance cost control policies still being implemented, the Q3 financial report continues to explore the bottom line of the business climate, with a recovery slower than expected.
Yifeng Pharmacy: Yifeng Pharmacy Report for the Third Quarter of 2024
Yifeng Pharmacy Report for the Third Quarter of 2024
No Data
No Data